NEW YORK (GenomeWeb News) – Exiqon today reported a 5 percent increase year over year in its revenues for 2013, while revenues in its fourth quarter shrank 16 percent.

The Danish firm said that total revenues in 2013 grew to DKK123.6 million ($22.6 million) from DKK117.4 million in 2012. Life Sciences revenues rose 6 percent to DKK118.4 million from DKK111.3 million, offsetting a 15 percent drop in Diagnostics revenues to DKK5.2 million from DKK6.1 million, Exiqon said in its annual report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.